Bishop W R, August J, Petrin J M, Pai J K
Department of Microbiology, Schering-Plough Research, Bloomfield, NJ 07003.
Biochem J. 1990 Jul 15;269(2):465-73. doi: 10.1042/bj2690465.
Stimulation of platelets with thrombin leads to rapid degradation of inositol phospholipids, generation of diacylglycerol (DAG) and subsequent activation of protein kinase C (PKC). Previous studies indicated that prior activation of PKC with phorbol myristate acetate (PMA) desensitizes platelets to thrombin stimulation, as indicated by a decreased production of inositol phosphates and decreased Ca2+ mobilization. This suggests that PKC activation generates negative-feedback signals, which limit the phosphoinositide response. To test this hypothesis further, we examined the effects of PKC activators and inhibitors on thrombin-stimulated DAG mass formation in platelets. Pretreatment with PMA abolishes thrombin-stimulated DAG formation (50% inhibition at 60 nM). Pretreatment of platelets with the PKC inhibitors K252a or staurosporine potentiates DAG production in response to thrombin (3-4-fold) when using concentrations required to inhibit platelet PKC (1-10 microM). K252a does not inhibit phosphorylation of endogenous DAG or phosphorylation of a cell-permeant DAG in unstimulated platelets, indicating that DAG over-production is not due to inhibition of DAG kinase. Sphingosine, a PKC inhibitor with a different mechanism of action, also potentiates DAG formation in response to thrombin. Several lines of evidence indicate that DAG formation under the conditions employed occurs predominantly by phosphoinositide (and not phosphatidylcholine) hydrolysis: (1) PMA alone does not elicit DAG formation, but inhibits agonist-stimulated DAG formation; (2) thrombin-stimulated DAG formation is inhibited by neomycin (1-10 mM) but not by the phosphatidate phosphohydrolase inhibitor propranolol; and (3) no metabolism of radiolabelled phosphatidylcholine was observed upon stimulation by thrombin or PMA. These data provide strong support for a role of PKC in limiting the extent of platelet phosphoinositide hydrolysis.
用凝血酶刺激血小板会导致肌醇磷脂迅速降解,生成二酰基甘油(DAG),随后激活蛋白激酶C(PKC)。先前的研究表明,用佛波醇肉豆蔻酸酯乙酸酯(PMA)预先激活PKC会使血小板对凝血酶刺激脱敏,这表现为肌醇磷酸产量降低和Ca2+动员减少。这表明PKC激活会产生负反馈信号,从而限制磷酸肌醇反应。为了进一步验证这一假设,我们研究了PKC激活剂和抑制剂对凝血酶刺激的血小板中DAG质量形成的影响。用PMA预处理可消除凝血酶刺激的DAG形成(60 nM时抑制50%)。当使用抑制血小板PKC所需的浓度(1 - 10 microM)时,用PKC抑制剂K252a或星形孢菌素预处理血小板会增强凝血酶刺激的DAG产生(3 - 4倍)。K252a不会抑制未刺激血小板中内源性DAG的磷酸化或细胞渗透性DAG的磷酸化,这表明DAG过度产生不是由于DAG激酶的抑制。鞘氨醇是一种作用机制不同的PKC抑制剂,也会增强凝血酶刺激的DAG形成。几条证据表明,在所采用的条件下,DAG形成主要通过磷酸肌醇(而非磷脂酰胆碱)水解发生:(1)单独的PMA不会引发DAG形成,但会抑制激动剂刺激的DAG形成;(2)凝血酶刺激的DAG形成受到新霉素(1 - 10 mM)的抑制,但不受磷脂酸磷酸水解酶抑制剂普萘洛尔的抑制;(3)在凝血酶或PMA刺激下未观察到放射性标记的磷脂酰胆碱的代谢。这些数据为PKC在限制血小板磷酸肌醇水解程度方面的作用提供了有力支持。